Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sunil Bhoyrul

Surgery La Jolla, CA Medical Doctor

NPI 1366559320 CMS profile 197903

9850 Genesee Ave, 570, La Jolla, CA 92037

Open in the dashboard

General payments

$57,791

226 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,952 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sunil Bhoyrul of La Jolla, CA is reported in the CMS Open Payments database as having received $57,791 across 226 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,952 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,387 37
2024 General $15,556 58
2023 General $21,829 56
2022 General $3,309 31
2021 General $908 21
2020 General $317 6
2019 General $1,484 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunil Bhoyrul
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Sunil Bhoyrul were reported at $14,387. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Sunil Bhoyrul Surgery median Middle half National median
2019 $1,484 $253 $82–$1,521 $163
2020 $317 $131 $40–$706 $114
2021 $908 $168 $50–$904 $132
2022 $3,309 $224 $76–$1,218 $149
2023 $21,829 $253 $82–$1,255 $160
2024 $15,556 $279 $90–$1,381 $164
2025 $14,387 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $26,521 79 payments
  2. Intuitive Surgical, Inc. $16,396 46 payments
  3. Medical Device Business Services, Inc. $10,426 15 payments
  4. Ethicon US, LLC $1,502 28 payments
  5. Allergan Inc. $1,024 9 payments
  6. Covidien LP $668 12 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $295 4 payments
  8. Novo Nordisk Inc $262 9 payments
  9. Teleflex LLC $237 6 payments
  10. TELA Bio, Inc. $169 3 payments
  11. Other $292 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,995 5 payments
  2. Education $10,832 10 payments
  3. Travel and Lodging $10,262 35 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,893 6 payments
  5. Food and Beverage $8,794 169 payments
  6. Gift $16 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $10,750 5 payments
  2. Signia $9,251 53 payments
  3. Echelon; Endopath $8,596 10 payments
  4. Harmonic $8,445 10 payments
  5. SURGICEL NU-KNIT $8,080 2 payments
  6. LigaSure $6,936 14 payments
  7. Da Vinci Surgical System $5,646 41 payments
  8. ALLODERM $996 8 payments
  9. Echelon Flex $522 7 payments
  10. ECHELON ENDOPATH $334 6 payments
  11. Other $2,647 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

85

Median for General Surgery: 59

Drug cost

$30,661

Median for General Surgery: $393

Branded share of claims

35.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 30 $30,513
Ondansetron Hcl Generic 14 $84
Tramadol Hcl Generic 41 $64

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$149,309

Medicare's payments for the services billed

Medicare patients

252

Average age 72

Services billed

714

156 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 42%
Chronic kidney disease 35%
Ischemic heart disease 33%
Depression 33%
Heart failure 28%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record